Addition of retinoic acid to chemotherapy improves survival of patients with acute myeloid leukemia. This effect is more pronounced in leukemias that express high levels of PRAME. PRAME is an inhibitor of retinoic acid signaling, which may prove to be an important marker for retinoic acid response.
- Received February 26, 2013.
- Accepted March 15, 2013.
- Copyright © 2013, American Association for Cancer Research.